World Health Organization Issues Alert Over Acute Scarcity of Weight-Loss Injections

Under 10% of patients who could benefit from obesity jabs including Wegovy have access to them, states the WHO as it issues its inaugural recommendations on the drugs.

Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just access to these injectable treatments.

According to forecasts, more than two billion will be obese by 2030 without intervention.

"Our latest guidance acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are key hurdles to universal access to the injections that can aid individuals in losing considerable body mass, explains the body.

GLP-1 Therapy Scarcity

Even under the current best projected scenario, the production of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of those who need them, per the WHO.

The guideline urges governments and firms to widen availability, by measures including patent sharing.

Exclusive production rights on semaglutide – the core component of the drug Wegovy – is set to lapse in several nations in 2026.

The Way Obesity Drugs Function

These medications imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost satiety so people consume fewer calories.

People commonly begin shedding pounds within a few weeks of commencing the weekly injections.

Studies points to people may regain a significant portion within a year of halting the treatment, because their usual hunger resume.

Being above a healthy weight elevates your likelihood for developing health problems, such as diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight affects people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.